It is worth noting that drug technologies with a high level of innovation focus on rare diseases and oncology, and the creation of the TLI list, focuses on promising therapies offered for these conditions.
AOTMiT determines the level of innovation and the conditions for the creation of this list with particular regard to the expected health effects, taking into account, among other things, the strength of the intervention, the quality of scientific data, the unmet health need, the size of the target population and health priorities. The extent of this data is extremely important because drugs with a high level of innovation that would be subject to funding are relatively short-lived on the market, and this implies a high degree of uncertainty in the application.
The creation of the TLI list is the first stage of the reimbursement process for highly innovative drug technologies. The next is the creation of the TLI list by the Minister of Health after prior consultation with the Transparency Council, National Consultants and the Patient Ombudsman. Placing a technology on the Minister of Health's TLI l...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
